Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2026 · second_quarter · Q2
Monitor health and tax legislation related to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2026 · first_quarter · Q1
Source: Senate LDA
Monitor health and tax legislation related to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2025 · fourth_quarter · Q4
Monitor health and tax legislation related to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2025 · third_quarter · Q3
Monitor health and tax legislation related to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2025 · second_quarter · Q2
Monitor health and tax legislation related to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2025 · first_quarter · Q1
Monitor health and tax legislation related to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2024 · fourth_quarter · Q4
Monitor health and tax issues relating to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2024 · third_quarter · Q3
Monitor health and tax issues relating to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2024 · second_quarter · Q2
Monitor health and tax issues relating to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2024 · first_quarter · Q1
Monitor health and tax issues relating to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2023 · fourth_quarter · Q4
Monitor health and tax issues relating to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2023 · third_quarter · Q3
Monitor health and tax issues relating to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2023 · second_quarter · Q2
Monitor health and tax issues relating to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2023 · first_quarter · Q1
Monitor health and tax issues relating to biotechnology industry.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2022 · fourth_quarter · Q4
Monitor health and tax legislation relating to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2022 · third_quarter · Q3
Monitor health and tax legislation relating to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2022 · second_quarter · Q2
Monitor health and tax legislation relating to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2022 · first_quarter · Q1
Monitor health and tax legislation relating to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2021 · fourth_quarter · Q4
Monitor health and tax legislation relating to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2021 · third_quarter · Q3
Monitor health and tax legislation relating to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2021 · second_quarter · Q2
Monitor health and tax legislation relating to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2021 · first_quarter · Q1
Monitor health and tax legislation relating to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2020 · fourth_quarter · Q4
Support legislation to strengthen the U.S. patent system
Meetings regarding proposed changes to Medicare Part B and Part D reimbursement that negatively impact patient access to innovative therapies
Support legislation to fund the National Institutes of Health for Fiscal Year 2022
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2020 · third_quarter · Q3
Support legislation to strengthen the U.S. patent system
Monitor legislation to change 340B Discount Drug Program
Support legislation to fund the National Institutes of Health for Fiscal Year 2021
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2020 · second_quarter · Q2
Issues associated with legislative and administrative proposals regarding the pricing of biopharmaceuticals, including biosimilars
Support legislation to fund the National Institutes of Health for Fiscal Year 2021
Monitor health and tax legislation related to biotechnology industry
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2020 · first_quarter · Q1
Monitor health and tax legislation related to biotechnology industry
Monitor legislation to change 340B Discount Drug Program
Meetings regarding proposed changes to Medicare Part B and Part D reimbursement that negatively impact patient access to innovative therapies
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2019 · fourth_quarter · Q4
Issues associated with legislative and administrative proposals regarding the pricing of biopharmaceuticals, including biosimilars
Meetings regarding proposed changes to Medicare Part B and Part D reimbursement that negatively impact patient access to innovative therapies
Monitor health and tax legislation related to biotechnology industry
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2019 · third_quarter · Q3
Support legislation to strengthen the U.S. patent system
Monitor legislation to change 340B Discount Drug Program
Monitor health and tax legislation related to biotechnology industry
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2019 · second_quarter · Q2
Support legislation to strengthen the U.S. patent system
Monitor legislation to change 340B Discount Drug Program
Monitor health and tax legislation related to biotechnology industry
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2019 · first_quarter · Q1
Support legislation to strengthen the U.S. patent system
Support legislation to fund the National Institutes of Health for Fiscal Year 2020
Issues associated with legislative and administrative proposals regarding the pricing of biopharmaceuticals, including biosimilars
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2018 · fourth_quarter · Q4
Monitor health and tax legislation ptertaining to bioltechnology industry.
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.
Support legislation to strengthen U.S. Patent System
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2018 · third_quarter · Q3
Monitor health and tax legislation ptertaining to bioltechnology industry.
Meetings regarding issues associated with the Patient Protection and Affordable Care Act's and alternative legislation's impact on the biotechnology industry, including issues related to biosimilars, the Independent Payment and Advisory Board and use of comparative effectiveness research.
Support legislation to strengthen U.S. Patent System
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2018 · second_quarter · Q2
Support legislation to strengthen U.S. Patent System
Monitor health and tax legislation ptertaining to bioltechnology industry.
Support legislation to fund the National Institutes of Health for Fiscal Year 2019
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2018 · first_quarter · Q1
Support legislation to fund the National Institutes of Health for Fiscal Year 2019
Meetings regarding issues associated with the Patient Protection and Affordable Care Act's and alternative legislation's impact on the biotechnology industry, including issues related to biosimilars, the Independent Payment and Advisory Board and use of comparative effectiveness research.
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2017 · fourth_quarter · Q4
Meetings regarding issues associated with the Patient Protection and Affordable Care Act's and alternative legislation's impact on the biotechnology industry, including issues related to biosimilars, the Independent Payment and Advisory Board and use of comparative effectiveness research.
Support legislation to strengthen U.S. Patent System
Support legislation to fund the National Institutes of Health for Fiscal Year 2019
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2017 · third_quarter · Q3
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.
Monitor health and tax legislation ptertaining to bioltechnology industry.
Support legislation to strengthen U.S. Patent System
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2017 · second_quarter · Q2
Monitor health and tax legislation ptertaining to bioltechnology industry.
Support legislation to fund the National Institutes of Health for Fiscal Year 2018
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2017 · first_quarter · Q1
Support legislation to fund the National Institutes of Health for Fiscal Year 2018
Monitor health and tax legislation ptertaining to bioltechnology industry.
Meetings regarding issues associated with the Patient Protection and Affordable Care Act's impact on the biotechnology industry, including issues related to biosimilars, the Independent Payment and Advisory Board and use of comparative effectiveness research.
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2016 · fourth_quarter · Q4
Meetings regarding issues associated with the Patient Protection and Affordable Care Act impacting the biotechnology industry, including issues related to biosimilars, the Independent Payment Advisory Board and use of comparative effectiveness research.
Support legislation to strengthen U.S. Patent System
Support legislation to fund National Institutes of Health
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2016 · third_quarter · Q3
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies
Support legislation to strengthen U.S. Patent System
Support legislation to fund National Institutes of Health
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2016 · second_quarter · Q2
Support legislation to fund National Institutes of Health
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies
Meetings regarding issues associated with the implementation of the Patient Protection and Affordable Care Act impacting the biotechnology industry, including issues related to biosimilars, the Independent Payment Advisory Board and use of comparative effectiveness research.
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2016 · first_quarter · Q1
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies
Meetings regarding issues associated with the implementation of the Patient Protection and Affordable Care Act impacting the biotechnology industry, including issues related to biosimilars, the Independent Payment Advisory Board and use of comparative effectiveness research.
Support legislation to fund National Institutes of Health
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2015 · fourth_quarter · Q4
Support legislation to strengthen U.S. Patent System
Meetings regarding issues associated with the implementation of the Patient Protection and Affordable Care Act impacting the biotechnology industry, including issues related to biosimilars, the Independent Payment Advisory Board and use of comparative effectiveness research.
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2015 · third_quarter · Q3
Support legislation to strengthen U.S. Patent System
Support legislation to fund National Institutes of Health
Meetings regarding issues associated with the implementation of the Patient Protection and Affordable Care Act impacting the biotechnology industry, including issues related to biosimilars, the Independent Payment Advisory Board and use of comparative effectiveness research.
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2015 · second_quarter · Q2
Support legislation to fund National Institutes of Health
Support legislation to strengthen U.S. Patent System
Meetings regarding issues associated with the implementation of the Patient Protection and Affordable Care Act impacting the biotechnology industry, including issues related to biosimilars, the Independent Payment Advisory Board and use of comparative effectiveness research.
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2015 · first_quarter · Q1
Support legislation to strengthen U.S. Patent System
Meetings regarding issues associated with the implementation of the Patient Protection and Affordable Care Act impacting the biotechnology industry, including issues related to biosimilars, the Independent Payment Advisory Board and use of comparative effectiveness research.
Support legislation to fund National Institutes of Health
MASSACHUSETTS BIOTECHNOLOGY COUNCIL via PARK STREET STRATEGIES, LLC
2015 · first_quarter · RR
Issues associated with the implementation of the Patient Protection and Affordable Care Act impacting the biotechnology industry
Issues associated with legislative and administrative proposals regarding the pricing of biopharmaceuticals, including biosimilars
Monitor legislation to change 340B Discount Drug Program
Monitor health and tax legislation related to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Meetings regarding proposed changes to Medicare Part B and Part D reimbursement that negatively impact patient access to innovative therapies
Monitor health and tax legislation related to biotechnology industry
Issues associated with legislative and administrative proposals regarding the pricing of biopharmaceuticals, including biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to strengthen the U.S. patent system
Monitor legislation to change 340B Discount Drug Program
Meetings regarding proposed changes to Medicare Part B and Part D reimbursement that negatively impact patient access to innovative therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to strengthen the U.S. patent system
Support legislation to fund the National Institutes of Health for Fiscal Year 2021
Issues associated with legislative and administrative proposals regarding the pricing of biopharmaceuticals, including biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Monitor legislation to change 340B Discount Drug Program
Support legislation to fund the National Institutes of Health for Fiscal Year 2020
Support legislation to strengthen the U.S. patent system
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to fund the National Institutes of Health for Fiscal Year 2020
Meetings regarding proposed changes to Medicare Part B and Part D reimbursement that negatively impact patient access to innovative therapies
Issues associated with legislative and administrative proposals regarding the pricing of biopharmaceuticals, including biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to fund the National Institutes of Health for Fiscal Year 2020
Issues associated with legislative and administrative proposals regarding the pricing of biopharmaceuticals, including biosimilars
Meetings regarding proposed changes to Medicare Part B and Part D reimbursement that negatively impact patient access to innovative therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Meetings regarding proposed changes to Medicare Part B and Part D reimbursement that negatively impact patient access to innovative therapies
Monitor legislation to change 340B Discount Drug Program
Monitor health and tax legislation related to biotechnology industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to fund the National Institutes of Health for Fiscal Year 2019
Meetings regarding issues associated with the Patient Protection and Affordable Care Act's and alternative legislation's impact on the biotechnology industry, including issues related to biosimilars, the Independent Payment and Advisory Board and use of comparative effectiveness research.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to fund the National Institutes of Health for Fiscal Year 2019
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Meetings regarding issues associated with the Patient Protection and Affordable Care Act's and alternative legislation's impact on the biotechnology industry, including issues related to biosimilars, the Independent Payment and Advisory Board and use of comparative effectiveness research.
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Monitor health and tax legislation ptertaining to bioltechnology industry.
Support legislation to strengthen U.S. Patent System
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Monitor health and tax legislation ptertaining to bioltechnology industry.
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to fund the National Institutes of Health for Fiscal Year 2018
Meetings regarding issues associated with the Patient Protection and Affordable Care Act's and alternative legislation's impact on the biotechnology industry, including issues related to biosimilars, the Independent Payment and Advisory Board and use of comparative effectiveness research.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to strengthen U.S. Patent System
Meetings regarding issues associated with the Patient Protection and Affordable Care Act's and alternative legislation's impact on the biotechnology industry, including issues related to biosimilars, the Independent Payment and Advisory Board and use of comparative effectiveness research.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to strengthen U.S. Patent System
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Meetings regarding issues associated with the implementation of the Patient Protection and Affordable Care Act impacting the biotechnology industry, including issues related to biosimilars, the Independent Payment Advisory Board and use of comparative effectiveness research.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to strengthen U.S. Patent System
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to strengthen U.S. Patent System
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Support legislation to fund National Institutes of Health
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE